Marker Therapeutics (MRKR) Non-Current Debt (2015 - 2023)

Marker Therapeutics (MRKR) reported Non-Current Debt of $97400.0 for Q1 2023, up 508.75% quarter-over-quarter from $16000.0 in Q3 2022.

Marker Therapeutics (MRKR) Non-Current Debt (2015 - 2023) Analysis & Trends

Marker Therapeutics (MRKR) has 3 years of Non-Current Debt data on file, last reported at $97400.0 in Q1 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Non-Current Debt (Qtr)
1	Alterity Therapeutics	719,706.53 Bn	719,706.50 Bn	-	-
2	Belite Bio	55,800.00 Bn	55,800.00 Bn	-	-
3	Quantum Biopharma	18,182.30 Bn	18,182.29 Bn	-	-
4	Legend Biotech	3,154.00 Bn	3,153.71 Bn	242.10 Mn	319.10 Mn
5	Akari Therapeutics	1,844.30 Bn	1,844.29 Bn	-	-
6	Evaxion A	1,567.96 Bn	1,567.94 Bn	-	-
7	Psyence Biomedical	251.43 Bn	251.42 Bn	-	-
8	Vertex Pharmaceuticals	112.56 Bn	105.31 Bn	2.59 Bn	-
9	Abivax	94.37 Bn	94.37 Bn	-	-
10	Marker Therapeutics	28.20 Mn	28.20 Mn	-	-

Download Data